The role of targeted therapy and biomarkers in breast cancer treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The role of targeted therapy and biomarkers in breast cancer treatment

Published:2012-06-13 Issue:7 Volume:29 Page:807-819
ISSN:0262-0898
Container-title:Clinical & Experimental Metastasis
language:en
Short-container-title:Clin Exp Metastasis

Author:

Stopeck Alison T.,Brown-Glaberman Ursa,Wong Hong Yuen,Park Ben Ho,Barnato Sara E.,Gradishar William J.,Hudis Clifford A.,Rugo Hope S.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10585-012-9496-y.pdf

Reference94 articles.

1. Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

2. Marty MA et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265–4274

3. Cobleigh MA et al (2005) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648

4. Robert N et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786–2792

5. Wardley AM et al (2010) Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 28:976–983

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in siRNA delivery using nanotechnology for reproductive tract cancers: From targeting to enhancing treatment efficacy;Journal of Reproductive Healthcare and Medicine;2024-08-05

2. Biomarkers in Systemic Sclerosis;Scleroderma;2024

3. Combination Therapy of Lox Inhibitor and Stimuli‐Responsive Drug for Mechanochemically Synergistic Breast Cancer Treatment;Advanced Healthcare Materials;2023-05-11

4. Serum Leptin Level in Breast Cancer;Acta Clinica Croatica;2022

5. USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α;Cell Death & Disease;2021-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3